Source:http://linkedlifedata.com/resource/pubmed/id/21471647
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2011-7-11
|
| pubmed:abstractText |
The present study evaluated the effects of once-daily memantine (20 mg) treatment on cognition and communication in patients with moderate to severe Alzheimer's disease (AD). In a multicenter, single-arm open-label study, outpatients diagnosed with AD (MMSE < 20; n = 97) were titrated from 5 mg to 20 mg once-daily memantine over 4 weeks. Once-daily memantine treatment (20 mg) was then continued for 8 weeks, followed by a 4-week wash-out period. The primary efficacy endpoint was the change from baseline in the Consortium to Establish a Registry for Alzheimer's Disease -Neuropsychological Battery (CERAD-NP) total score. Secondary efficacy endpoints included change from baseline in Functional Communication Language Inventory (FLCI) and ADCS-ADL19 total score, and the response from baseline in Clinical Global Impression of Change (CGI-C). The CERAD-NP total score improved significantly after 12 weeks of once-daily memantine treatment compared with baseline (5.9 ± 8.8; p < 0.0001). The FLCI total score improved significantly after 12 weeks compared with baseline (4.4 ± 6.8; p < 0.0001). These significant improvements were already observed after 4 and 8 weeks of once-daily memantine treatment and persisted after a 4-week wash-out period. ADCS-ADL19 total scores showed only slight increases from baseline, and CGI-C indicated that the majority of patients experienced an improvement or stabilization of the disease after 12 weeks. At least one Treatment-Emergent Adverse Event was reported by 38 (39.2%) patients. In patients with moderate to severe AD, once-daily memantine (20 mg) treatment significantly improved cognition and functional communication and was found to have a favorable safety and tolerability profile.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1875-8908
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
25
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
463-75
|
| pubmed:meshHeading |
pubmed-meshheading:21471647-Activities of Daily Living,
pubmed-meshheading:21471647-Aged,
pubmed-meshheading:21471647-Aged, 80 and over,
pubmed-meshheading:21471647-Alzheimer Disease,
pubmed-meshheading:21471647-Cognition Disorders,
pubmed-meshheading:21471647-Communication,
pubmed-meshheading:21471647-Dose-Response Relationship, Drug,
pubmed-meshheading:21471647-Drug Administration Schedule,
pubmed-meshheading:21471647-Excitatory Amino Acid Antagonists,
pubmed-meshheading:21471647-Female,
pubmed-meshheading:21471647-Follow-Up Studies,
pubmed-meshheading:21471647-Humans,
pubmed-meshheading:21471647-Male,
pubmed-meshheading:21471647-Memantine,
pubmed-meshheading:21471647-Middle Aged,
pubmed-meshheading:21471647-Neuropsychological Tests,
pubmed-meshheading:21471647-Psychiatric Status Rating Scales,
pubmed-meshheading:21471647-Reproducibility of Results,
pubmed-meshheading:21471647-Speech Disorders
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial.
|
| pubmed:affiliation |
Department of Neurology, University Medical Center, RWTH Aachen, Aachen, Germany. jschulz@ukaachen.de
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|